TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15282384
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP; 250 microg twice daily) for 2 weeks
Study: 9602688
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg for 30 to 40 days (mean 35)
Study: 9602688
Drug: Azithromycin 1000
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1000 mg for 21 to 50 days (mean 37)
Study: 9602688
Drug: Azithromycin 1500
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1500 mg for 20 days
Study: 9602688
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose maintenance treatment with azithromycin for 30 to 360 days (mean 129)
Study: 9602688
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term initial course of azithromycin (various doses)
Study: 7684157
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg once daily
Study: 2711711
Drug: Non‐medicamentous therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐medicamentous therapy (CNT)
Study: 2711711
Drug: Medicamentous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicamentous therapy
Study: 14253279
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 12.5, 25.0, 37.5, and 50.0 mg/kg
Study: 14253279
Drug: Hydroxyurea administered
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea administered parenterally
Study: 14253279
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 25.0, 37.5, and 50.0 mg/kg
Study: 14253279
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 12.5 mg/kg (low dose)
Study: 344159
Drug: Glucagon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (2 X 5 mg protamine-zinc glucagon intramuscularly per day)
Study: 29949284
Drug: Pertubation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertubation treatment
Study: 19967596
Drug: 6.4% carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate‐electrolyte solution
Study: 15126989
Drug: High-dose rhASB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhASB (1.0 mg/kg)
Study: 15126989
Drug: Low-dose rhASB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhASB (0.2 mg/kg)
Study: 12641012
Drug: Dose around
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose around 20 Gy of brachytherapy
Study: 12641012
Drug: Controlled dose
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled dose escalation of brachytherapy
Study: 9817690
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment (n = 11)
Study: 2570971
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol patches (2 x 100 micrograms) with norethisterone 5 mg from day 19-26 of the cycle
Study: 2570971
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches with norethisterone 5 mg from day 19-26 of the cycle
Study: 1233519
Drug: Oral diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam, 30 mgs. daily
Study: 30157115
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral iron supplementation (Control)
Study: 30157115
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation in hypertensive participants
Study: 30157115
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation in hypertensive participants without anemia
Study: 28501522
Drug: Flosequinan (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (75 or 100 mg/day)
Study: 9872520
Drug: OAC (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole)
Study: 9872520
Drug: Ox2AC (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ox2AC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg b.i.d. omeprazole)
Study: 9872520
Drug: OACS (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: OACS (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole, 100 mg t.i.d. sofalcone)
Study: 7913155
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate (50 micrograms twice daily) plus BDP
Study: 7913155
Drug: Higher-dose BDP
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose BDP (500 micrograms twice daily)
Study: 2915235
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years)
Study: 2915235
Drug: Standard VAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard VAC therapy for 2 years or VA for 1 year (Control)
Study: 1104047
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg/day
Study: 1104047
Drug: Atenolol 400
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 400 mg/day
Study: 1104047
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg/day with bendrofluazide 5 mg/day
Study: 1104047
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg/day
Study: 21987394
Drug: Gantenerumab 60
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab 60 mg
Study: 21987394
Drug: Gantenerumab 200
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab 200 mg
Study: 20367671
Drug: Hydroglycolic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroglycolic extract of Piptadenia colubrina (HEPC) in a gel-cream formulation
Study: 15909264
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy (mold-active antifungal drugs)
Study: 108715
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg haloperidol intravenous (IV)
Study: 108715
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg haloperidol intravenous (IV)
Study: 108715
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg haloperidol intramuscular (IM)
Study: 108715
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg haloperidol intramuscular (IM)
Study: 30745518
Drug: Fosravuconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosravuconazole (100 mg orally once a day for 12 weeks)
Study: 28599665
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs capsules (1.8g EPA and 1.2g DHA)
Study: 25796419
Drug: Silver sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver sucrose octasulfate nasal gel (Silsos gel®)
Study: 25022114
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (acupuncture and auricle cutting)
Study: 18322606
Drug: Routine medications
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medications
Study: 6544198
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sulindac twice daily
Study: 22101443
Drug: Ward care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward care (for patients with anaerobic threshold >= 11 ml oxygen per kg per min)
Study: 20696797
Drug: Quality Initiative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Quality Initiative in Rectal Cancer strategy
Study: 14555886
Drug: Beta-blocker bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker bisoprolol (5 mg/day)
Study: 9307933
Drug: 3.8 g
Normalized name: dextrin 3 gram/3.8 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.8 g highly purified EPA
Study: 9307933
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g DHA
Study: 8165609
Drug: Bay u3405
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay u3405 (thromboxane A2 receptor antagonist)
Study: 3532011
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micrograms twice daily via pear spacer (PS)
Study: 3532011
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micrograms twice daily directly from metered dose inhaler
Study: 27654255
Drug: Vintafolide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vintafolide (2.5 mg intravenously, 3 times per week, weeks 1 and 3, every 28 days) + Pegylated Liposomal Doxorubicin (50 mg/m intravenously, day 1, every 28 days)
Study: 27654255
Drug: Pegylated Liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Liposomal Doxorubicin alone (50 mg/m intravenously, day 1, every 28 days)
Study: 27654255
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Vintafolide + PLD)
Study: 19935406
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid at doses of 15, 30, and 50 mg/kg per day
Study: 17931082
Drug: Alikal Dolor
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alikal Dolor (effervescent powder containing paracetamol 500 mg/sodium bicarbonate 2318 mg)
Study: 17931082
Drug: Parageniol (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parageniol (paracetamol 500 mg coated tablets)
Study: 15848672
Drug: Prograf twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf twice a day (days 14 and 42)
Study: 15848672
Drug: MR tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR tacrolimus once daily (days 28 and 56)
Study: 15848672
Drug: Prograf twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf twice a day (day 14)
Study: 15848672
Drug: MR tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR tacrolimus once daily (day 28)
Study: 15848672
Drug: Prograf twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf twice a day (day 42)
Study: 15848672
Drug: MR tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR tacrolimus once daily (day 56)
Study: 11973248
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment for up to 6 weeks
Study: 11973248
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment for 4 or more weeks
Study: 30717690
Drug: Intravenous Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Iron sucrose complex (ISC)
Study: 28527704
Drug: PF-00547659 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547659 7.5 mg
Study: 28982740
Drug: PF-00547659 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547659 22.5 mg
Study: 28982740
Drug: PF-00547659 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547659 75 mg
Study: 28982740
Drug: PF-00547659 225
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547659 225 mg
Study: 25746580
Drug: α‐adrenergic agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐adrenergic agonist (midodrine) plus an anticholinergic (solifenacin)
Study: 25746580
Drug: α‐adrenergic agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐adrenergic agonist only
Study: 16974184
Drug: Olanzapine (OLZ)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLZ) 10-20 mg/d
Study: 16974184
Drug: Quetiapine (QUE)
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine (QUE) 300-700 mg/d
Study: 11279409
Drug: Off-pump treatment
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-pump treatment on the beating heart
Study: 11279409
Drug: On-pump treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-pump treatment with conventional cardiopulmonary bypass
Study: 9253309
Drug: Carbimazole by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole by a titration regimen (Group A, n = 30)
Study: 9253309
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of carbimazole plus T4 (Group B, n = 30)
Study: 8463869
Drug: Polysaccharide-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide-free diet with 20 g of unabsorbed sugar lactulose
Study: 8463869
Drug: Polysaccharide-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide-free diet with 20 g of fermentable fiber, guar
Study: 2834257
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg every 6 h s.c.)
Study: 2834257
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg every 6 h s.c.)
Study: 2834257
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline 1 ml every 6 h s.c.)
Study: 28158200
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control tool (CC)
Study: 25171663
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose triamcinolone hexacetonide (20 mg)
Study: 25171663
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose triamcinolone hexacetonide (40 mg)
Study: 9035015
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg bid (E200)
Study: 9035015
Drug: Etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 300 mg bid (E300)
Study: 9035015
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg qd (P20)
Study: 27402235
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose edoxaban
Study: 27402235
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose edoxaban
Study: 26386790
Drug: NOACs (meta-analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs (meta-analysis of 4 warfarin-controlled phase 3 AF trials)
Study: 21534652
Drug: Internet-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based therapy (TAO)
Study: 2865187
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive
Study: 14564679
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d for 12 weeks
Study: 10964188
Drug: Complementary therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary therapies (specific therapies not detailed)
Study: 10964188
Drug: Complementary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary therapy research methods
Study: 1620831
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 160‐mL dose of Optiray 320 (ioversol) at 3.0 mL/sec (group 1)
Study: 1620831
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 160‐mL dose of Optiray 320 (ioversol) at 4.5 mL/sec (group 2)
Study: 6736339
Drug: Oral 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA)
Study: 31237065
Drug: Ultramicronized palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultramicronized palmitoylethanolamide (PEA-um) 15 mg/kg per os, once daily; n=29
Study: 26718899
Drug: VAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC therapy in venous ulcers
Study: 25163699
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg lexaptepid
Study: 22161738
Drug: Iloperidone 10-16
Normalized name: iloperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 10-16 mg/day
Study: 22161738
Drug: Iloperidone 20-24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 20-24 mg/day
Study: 22161738
Drug: Iloperidone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (all doses)
Study: 22161738
Drug: Iloperidone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (higher doses)
Study: 17095745
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg every 8 h for 3 days)
Study: 17598699
Drug: Test FDC
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Study: 17598699
Drug: Reference FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Study: 9728854
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of clonidine (4 microg/kg in 20 min followed by 2 microg x kg(‐1) x h(‐1))
Study: 9728854
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of sufentanil (0.2 microg x kg(‐1) x h(‐1))
Study: 9728854
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of ketamine (0.5 mg/kg followed by 0.25 mg x kg(‐1) x h(‐1))
Study: 9728854
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine (7 mL of 0.5% followed by 5 mL/h of 0.25%)
Study: 2658536
Drug: Xylitol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (30 g in 200 mL water)
Study: 2658536
Drug: Glucose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (30 g in 200 mL water)
Study: 2658536
Drug: Xylitol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (30 g)
Study: 10944
Drug: Hydrochloride preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochloride preparation of oxytetracycline
Study: 10944
Drug: Film-coated tablets
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablets of oxytetracycline dihydrate
Study: 10944
Drug: Sugar-coated tablets
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated tablets of oxytetracycline dihydrate
Study: 30329224
Drug: CKD-395 0.5/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-395 0.5/1000 mg
Study: 30329224
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of lobeglitazone sulfate 0.5 mg and metformin HCl XR 1000 mg
Study: 26011583
Drug: High-frequency EMA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency EMA (six times daily)
Study: 26011583
Drug: Low-frequency EMA
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency EMA (once daily)
Study: 21959871
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy for all HER2-positive populations
Study: 21959871
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy for IHC 2+/FISH+ or IHC 3+ population
Study: 21959871
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy for IHC 3+ population
Study: 19843557
Drug: ALVAC-HIV (vCP1521)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP1521) plus AIDSVAX B/E vaccine regimen
Study: 12142757
Drug: Intraoperative retrobulbar
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative retrobulbar 95% ethanol injections
Study: 9990383
Drug: Topical betamethasone‐17‐valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone‐17‐valerate
Study: 9626025
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 micrograms twice daily
Study: 1972599
Drug: Salbutamol 400
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 400 micrograms twice daily
Study: 336450
Drug: Graded doses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded doses of lactose (0 to 18 g) in breakfast meals, randomized and double-blinded.